Retrophin, Inc. Provides Sales Guidance for the Fourth Quarter and Fiscal Year 2015
For the fiscal year 2015, the company expects total net product sales of approximately $99.9 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
10.29 USD | +0.68% |
|
+7.97% | +14.46% |
Jul. 01 | Travere Therapeutics, Inc.(NasdaqGM:TVTX) dropped from Russell 3000 Growth Index | CI |
Jul. 01 | Travere Therapeutics, Inc.(NasdaqGM:TVTX) dropped from Russell 3000E Growth Index | CI |
1st Jan change | Capi. | |
---|---|---|
+14.46% | 778M | |
+20.03% | 126B | |
+23.61% | 118B | |
+23.26% | 27.87B | |
-18.07% | 20.95B | |
-15.13% | 16.92B | |
-14.81% | 16.18B | |
+9.78% | 14.84B | |
-46.10% | 14.79B | |
+52.34% | 14.08B |